💊 Lupin Receives U.S. FDA Approval, Launches Sugammadex Injection in the U.S.

Lupin Ltd.** has received approval from the **U.S. Food and Drug Administration (FDA)** and launched **Sugammadex Injection** in the United States, strengthening its portfolio in the world's largest pharmaceutical market. The approved product is available in **200 mg/2 mL** and **500 mg/5 mL** single-dose vials and is bioequivalent to **Bridion® Injection** of Merck. Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by **rocuronium bromide** and **vecuronium bromide** in adults and pediatric patients aged two years and older undergoing surgery. ### 🔑 Key Highlights ✅ U.S. FDA approves Lupin's Sugammadex Injection ✅ Product launched immediately in the U.S. market ✅ Available in **200 mg/2 mL** and **500 mg/5 mL** single-dose vials ✅ Bioequivalent to Merck's **Bridion® Injection** ✅ Expands Lupin's U.S. injectable pharmaceuticals portfolio 📌 **Why It Matters:** The approval and commercial launch reinforce Lupin's presence in the U.S. generics market while enhancing its injectable product portfolio, supporting future growth opportunities. 👍 **Like | Share | Follow @AFS Trading Edge** for more market updates. ⚠️ **Disclaimer:** This post is for informational and educational purposes only and should not be considered investment advice.